Ведение больных с дифференцированными нейроэндокринными опухолями илеоеюнальной локализации (по материалам международных клинических рекомендаций)

Клинические рекомендации по ведению больных с нейроэндокринными опухолями дистальной части тонкой (тощей и подвздошной) кишки выработаны группой международных экспертов и освещают обновление эпидемиологических данных, пересмотр различных параметров классификации опухолей (ВОЗ, гистологические критерии, TNM), а также мультидисциплинарные проблемы, связанные с различными вопросами диагностики, стадирования и выбора оптимальных методов лечения больных с нейроэндокринными опухолями указанной локализации. Полный текст рекомендаций: B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Plоckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Kоrner, G. Rindi, S. Wildi et al. Neuroendocrinology. 2008;87:8–19.

1. B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Plоckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Kоrner, G. Rindi, S. Wildi et al. Neuroendocrinology – 2008, 87, р. 8–19.

2. Modlin I.M, Lye K. D., Kidd M. A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–959.

3. Kulke M.H., Mayer R.J. Carcinoid tumors. N. Engl. J. Med. 1999; 340: 858–868.

4. Burke A.P., Thomas R.M., Elsayed A.M., Sobin L.H. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79: 1086–1093.

5. Peck J.J., Shields A.B., Boyden A.M. et al. Carcinoid tumors of the ileum. Am. J. Surg. 1983; 146: 124–132.

6. Modlin I.M., Sandor A. An analysis of 8,305 cases of carcinoid tumors. Cancer 1997; 79: 813–829.

7. Loftus J.P., van Heerden J.A. Surgical management of gastrointestinal carcinoid tumors. Adv. Surg.1995; 28: 317–336.

8. Godwin J.D. 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36: 560– 569.

9. Solcia E.K.G., Sobin L.H. in collaboration with 9 pathologists from 4 countries: Histological Typing of Endocrine Tumors,ed 2. WHO International Histological Classification of Tumors. Berlin: Springer, 2000.

10. Berge T., Linell F. Carcinoid tumours. Frequency in a defined population during a 12year period. Acta Pathol. Microbiol. Scand. [A] 1976; 84: 322–330.

11. Strodel W.E., Talpos G., Eckhauser F., Thompson N. Surgical therapy for small-bowel carcinoid tumors. Arch. Surg. 1983; 118: 391–397.

12. Marshall J.B., Bodnarchuk G. Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J. Clin. Gastroenterol. 1993; 16: 123–129.

13. McDermott E.W., Guduric B., Brennan M.F. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br. J. Surg. 1994; 81: 1007–1009.

14. Arnold R., Rinke A., Klose K.J. et al. Octreotide versus octreotide plus interferonin endocrine gastroenteropancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol. 2005; 3: 761–771.

15. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr. Opin. Oncol. 1993; 5: 110–120.

16. Moertel C.G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J. Clin. Oncol. 1987; 5: 1502–1522.

17. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J. Surg. 1996; 20: 126–131.

18. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am. 1993; 22: 941–952.

19. Ahlman H., Westberg G., Wangberg B. et al. Treatment of liver metastases of carcinoid tumors. World. J. Surg. 1996; 20: 196–202.

20. Zuetenhorst J.M., Bonfrer J.M., Korse C.M. et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factorand fibroblast growth factor. Cancer 2003; 97: 1609–1615.

21. Norheim I., Oberg K., Theodorsson-Norheim E. et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann. Surg. 1987; 206: 115–125.

22. Makridis C., Rastad J., Oberg K., Akerstrom G. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J. Surg. 1996; 20: 900– 907.

23. Westberg G., Wangberg B., Ahlman H. et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br. J. Surg. 2001; 88: 865–872.

24. Krenning E.P., Kwekkeboom D.J., Bakker W.H. et al. Somatostatin receptor scintigraphy with [ 111 In-DTPAD Phe 1 ]and [ 123 I-Tyr 3 ]octreotide: the Rotterdam experience with more than 1,000 patients. Eur. J. Nucl. Med. 1993; 20: 716–731.

25. Hofmann M., Maecke H., Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001; 28: 1751–1757.

26. Ricke J., Klose K.J., Mignon M. et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur. J. Radiol. 2001; 37: 8–17.

27. Kaltsas G., Rockall A., Papadogias D. et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 2004; 151: 15–27.

28. Bader T.R., Semelka R.C., Chiu V.C. et al. MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 2001; 14: 261–269.

29. Orlefors H., Sundin A., Garske U. et al. Wholebody 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J. Clin. Endocrinol. Metab. 2005; 90: 3392–3400.

30. Koopmans K.P., de Vries E.G., Kema I.P. et al. Staging of carcinoid tumours with 18 F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7: 728–734.

31. Van Tuyl S.A., van Noorden J.T., Timmer R. et al. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest. Endosc. 2006; 64: 66–72.

32. Swain P. Wireless capsule endoscopy. Gut 2003; 52 (suppl.4):48–50.

33. Oberg K., Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv. Exp. Med. Biol. 2000; 482: 329–337.

34. Ardill J.E., Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr. Relat. Cancer 2003; 10: 459–462.

35. Feldman J.M., O’Dorisio T.M. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am. J. Med. 1986; 81: 41–48.

36. Eriksson B., Oberg K. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol. 1991; 30: 477– 483.

37. Hamilton S.R. AL: Tumors of the digestive system. Pathology and Genetics. WHO Classification of Tumours. Lyon: ARC Press, 2000.

38. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395–401.

39. Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204–2210.

40. Hemminki K., Li X. Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int. J. Cancer 2001; 94: 444–448.

41. Akerstrom G., Makridis C., Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol.1991; 30: 547–553.

42. Rothmund M., Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55 (suppl. 3): 86–91.

43. Ahlman H., Wangberg B., Jansson S. et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(suppl 1):59–68.

44. Makridis C., Oberg K., Juhlin C. et al. Surgical treatment of mid-gut carcinoid tumors. World J. Surg. 1990; 14: 377–384.

45. Norton J.A. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(suppl 3):98–103.

46. Goede A.C., Winslet M.C. Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal. Dis. 2003; 5: 123–128.

47. Frilling A., Rogiers X., Malago M. et al. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch. Surg. 1998; 383: 62–70.

48. Lehnert T., Knaebel H.P. Diagnosis and therapy of liver metastases of neuroendocrine tumors in German). Hirurg 1997; 68: 122–131.

49. Chen H., Hardacre J.M., Uzar A. et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J. Am. Coll. Surg. 1998; 187: 88– 93.

50. Que F.G., Nagorney D.M., Batts K.P. et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg. 1995; 169: 36–43.

51. Sarmiento J.M., Heywood G., Rubin J. et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J. Am. Coll. Surg. 2003; 197: 29–37.

52. Chamberlain R.S., Canes D., Brown K.T. et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J. Am. Coll. Surg. 2000; 190: 432–445.

53. Norton J.A., Warren R.S., Kelly M.G. et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134: 1057–1065.

54. Soreide O., Berstad T., Bakka A. et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111: 48–54.

55. Moertel C.G., Sauer W.G., Dockerty M.B., Baggenstoss A.H. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–912.

56. Dousset B., Saint-Marc O., Pitre J. et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J. Surg. 1996; 20: 908–915.

57. Chung M.H., Pisegna.J, Spirt M. et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954–962.

58. Wangberg B., Westberg G., Tylen U. et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.World J. Surg. 1996; 20: 892–899.

59. McEntee G.P., Nagorney D.M., Kvols L.K. et al. Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091–1096.

60. Eriksson B., Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann. Oncol. 1999; 10 (suppl. 2):S31–S38.

61. Eriksson B., Renstrup J., Imam H., Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann. Oncol. 1997; 8: 1041–1044.

62. Wymenga A.N., Eriksson B., Salmela P.I. et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol. 1999; 17: 1111.

63. Ducreux M., Ruszniewski P., Chayvialle J.A. et аl. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. 2000; 95: 3276–3281.

64. Di Bartolomeo M., Bajetta E., Buzzoni R. et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402–408.

65. Arnold R., Trautmann M.E., Creutzfeldt W. et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430–438.

66. Aparicio T., Ducreux M., Baudin E. et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer 2001; 37: 1014–1019.

67. O’Toole D., Ducreux M., Bommelaer G. et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88: 770–776.

68. Ruszniewski P., Ducreux M., Chayvialle J.A. et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279–283.

69. Tomassetti P., Migliori M., Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am. J. Gastroenterol. 1998; 93: 1468–1471.

70. Tomassetti P., Migliori M., Corinaldesi R., Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol. Ther. 2000; 14: 557–560.

71. Faiss S., Pape U.F., Bohmig M. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – The International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 2003; 21: 2689–2696.

72. Rubin J., Ajani J., Schirmer W. et al. Octreotide acetate longacting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. 1999; 17: 600–606.

73. Ricci S., Antonuzzo A., Galli L. et al. Octreotide аcetate longacting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann. Oncol. 2000; 11: 1127–1130.

74. Leong W.L., Pasieka J.L. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J. Surg. Oncol. 2002; 79: 180–187.

75. Saltz L., Trochanowski B., Buckley M. et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244–248.

76. Plockinger U., Dienemann D., Quabbe H.J. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J. Clin. Endocrinol. Metab. 1990; 71: 1658–1662.

77. Oberg K., Norheim I., Lind E. et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat. Rep. 1986; 70: 1297–1304.

78. Valimaki M., Jarvinen H., Salmela P. et al. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67: 547–549.

79. Doberauer C., Mengelkoch B., Kloke O. et al. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon. Acta Oncol. 1991; 30: 603–605.

80. Creutzfeldt W., Bartsch H.H., Jacubaschke U., Stockmann F. Treatment of gastrointestinal endocrine tu mours with interferonand octreotide. Acta Oncol. 1991; 30: 529–535.

81. Moertel C.G., Rubin J., Kvols L.K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J. Clin. Oncol. 1989; 7: 865–868.

82. Janson E.T., Ronnblom L., Ahlstrom H. et al. Treatment with interferon versus α-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann. Oncol. 1992; 3: 635–638.

83. Oberg K., Alm G., Magnusson A. et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl. Cancer Inst. 1989; 81: 531–535.

84. Smith D.B., Scarffe J.H., Wagstaff J., Johnston R.J. Phase II trial of rDNA alfa-2b interferon in patients with malignant carcinoid tumor. Cancer Treat. Rep. 1987; 71: 1265–1266.

85. Tiensuu Janson E.M., Ahlstrom H., Andersson T., Oberg K.E. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur. J. Cancer 1992; 28A:1647–1650.

86. Jacobsen M.B., Hanssen L.E., Kolmannskog F. et al. Interferon-α 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian Carcinoid Study. Scand. J. Gastroenterol. 1995; 30: 789–796.

87. Dirix L.Y., Vermeulen P.B., Fierens H. et al. De Schepper B, Corthouts B., Van Oosterom A.T.: Long-term results of continuous treatment with recombinant interferon-α in patients with metastatic carcinoid tumors – an antiangiogenic effect? Anticancer. Drugs 1996; 7: 175–181.

88. Oberg K., Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991; 30: 519–522.

89. Nold R., Frank M., Kajdan U. et al. Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-α (in German). Z. Gastroenterol. 1994; 32: 193– 197.

90. Kolby L., Persson G., Franzen S., Ahren B. Randomized clinical trial of the effect of interferon-α on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. 2003; 90: 687–693.

91. Frank M., Klose K.J., Wied M. et al. Combination therapy with octreotide and α-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am. J. Gastroenterol. 1999; 94: 1381–1387.

92. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann. Oncol. 2001; 12 (suppl. 2): S111–S114.

93. Rougier P., Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 (suppl.1):73–78.

94. Pelley R.J., Bukowski R.M. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Curr. Opin. Oncol. 1999; 11: 32–37.

95. De Jong M., Breeman W.A., Bernard H.F. et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin analogues. Q. J. Nucl. Med. 1999; 43: 356–366.

96. De Jong M., Breeman W.A., Bakker W.H. et al. Comparison of 111 In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998; 58: 437–441.

97. Stolz B., Smith-Jones P., Albert R. et al. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996; 57 (suppl. 1):17–21.

98. Valkema R., De Jong M., Bakker W.H. et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin. Nucl. Med. 2002; 32: 110–122.

99. Waldherr C., Pless M., Maecke H.R. et al. The clinical value of [90 Y-DOTA]D -Phe 1 -Tyr 3 –octreotide (90 Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol. 2001; 12: 941–945.

100. Waldherr C., Pless M., Maecke H.R. et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBqY-DOTATOC. J. Nucl. Med. 2002; 43: 610–616.

101. Waldherr C., Schumacher T., Maecke H.R. et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90 Y-DOTATOC in neuroendocrine tumors? Eur. J. Nucl. Med. 2002; 29 (suppl.):S100.

102. Virgolini I., Britton K., Buscombe J. et al. Inand YDOTAlanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. 2002; 32: 148–155.

103. Virgolini I., Traub T., Novotny C. et al. Experience with indium-111 and yttrium-90labeled somatostatin analogs. Curr. Pharm. Des. 2002; 8: 1781–1807.

104. De Jong M., Bree man W.A., Bernard B.F. et al. Tumor response after [90 Y-DOTA 0, Tyr 3]oc treotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J. Nucl. Med. 2001; 42: 1841–1846.

105. Chinol M., Bodei L., Cremonesi M. Receptor-mediated radiotherapy with Y-DOTAD -Phe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin. Nucl. Med. 2002; 32: 141–147.

106. Paganelli G., Zoboli S., Cremonesi M. et al. Receptor-mediated radiotherapy with 90YDOTAD -Phe 1 -Tyr 3 -octreotide. Eur. J. Nucl. Med. 2001; 28: 426–434.

107. Valkema R., Kvols L., Jamar F. et al. Phase I study of therapy with 90 Y-SMT487 (OctreoTher) in patients with somatostatin receptorpositive tumors. J. Nucl. Med. 2002; 5 (suppl.):33P.

108. Bodei L., Cremonesi M., Zoboli S. et al. Receptormediated radionuclide therapy with 90 Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 207–216.

109. Rolleman E.J., Valkema R., de Jong M. et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 9–15.

110. Bushnell D., O’Dorisio T., Menda Y. et al. Evaluating the clinical effectiveness of 90 YSMT487 in patients with neuroendocrine tumors. J. Nucl. Med. 2003; 44: 1556–1560.

111. De Jong M., Breeman W.A., Bernard B.F. et al. [177 LuDOTA 0 ,Tyr 3 ]octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 2001; 92: 628–633.

112. Kwekkeboom D.J., Bakker W.H., Kooij P.P. et al. [177 LuDOTA 0, Tyr 3] octreotate: comparison with [ 111 In-DTPA 0 ] octreotide in patients. Eur. J. Nucl. Med. 2001; 28: 1319–1325.

113. De Jong M., Bernhard H.F, Breeman W.A.P. et al. Combination of 90 Yand 177 Lu-labeled somatostatin analogs in superior for radionuclide therapy compared to 90 Yor 177 Lulabeled analogs only. J. Nucl. Med. 2002: 123–124.

114. Kwekkeboom D.J., Bakker W.H., Kam B.L. et al. Treatment of patients with gastroenteropancreatic tumours with the novel radiolabelled somatostatin analogue 177 LuDOTA 0, Tyr 3] octreotate. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 417–422.

115. Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al. Radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005; 23: 2754–2762.

116. Jacobsen M.B., Nitter-Hauge S., Bryde P.E., Hanssen L.E. Cardiac manifestations in mid-gut carcinoid disease. Eur. Heart. J. 1995; 16: 263–268.

117. Gustafsson B.I., Tommeras K., Nordrum I. et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111: 1517–1522.

118. Zuetenhorst J.M., Korse C.M., Bonfrer J.M. et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br. J. Cancer 2004; 90: 2073–2079.